Prevention and Control of viral hepatitis in Israel: Lesson Learnt and the way forward.

14-15 March 2013 - Jerusalem, Israel

Thursday, March 14, 2013

Session 1 Introduction
Chair: Daniel Shouval, Pierre Van Damme

08.30 - 08.45

  • Welcome and opening
  • Introduction of the participants
  • Introduction of the VHPB.  1.8 Mb(.pdf) by Pierre Van Damme
  • Welcome by Boaz Lev, Associate Director General, ministry of Health, State of Israel
  • Welcome on behalf of the Israëli team by Daniel Shouval
  • Objectives of the meeting:
    • Provide an overview of surveillance systems for infectious diseases;
    • Review the epidemiological situation on viral hepatitis;
    • Give an overview of the current prevention and control measures on viral hepatitis;
    • Discuss the progress achieved in hepatitis prevention;
    • Review the possible implementation of new prevention strategies, control measures and monitoring systems.
    • Discuss the successes, issues and barriers to overcome, and the way forward
  • Pre-meeting document  436KB (.pdf)

Session 2 The health care system in the country
Chair: Nedret Emiroglu, Emilia Anis

08.45 – 09.05
Organization of public health services in Israel.  1.5Mb (.pdf)
Emilia Anis, Director, Division of Epidemiology, Ministry of Health

09.05 – 09.25
Organization and funding of the Healthcare system
Gabi Bin-Nun, Department of Health Management, Ben-Gurion university, Beer Sheba

09.25 – 09.45
Treatment policies and access to treatment for chronic hepatitis B and C.   361Kb (.pdf)
Tal Morginstin,  Director of the NLHS (National list of health services) Assessment Division at the Ministry of Health

09.45 – 10.05
National program for surveillance and control of viral hepatitis.   290Kb (.pdf)
Emilia Anis, Director, Division of Epidemiology, Ministry of Health

10.05 – 10.30 Discussion

10.30 – 10.50 Coffee Break

Session 3 Epidemiology of viral hepatitis in Israel
Chair: Françoise Roudot-Thoraval, Eli Zuckerman

10.50 – 11.10
Epidemiology of hepatitis A.   1.6Mb (.pdf)
Daniel Shouval, Liver Unit, Hadassah-Hebrew University, Jerusalem

11.10 – 11.30
Epidemiology of hepatitis B and C.  314Kb (.pdf)
Eli Zuckerman,  Director, Liver Unit, Carmel Medical Center and Haifa and Western Galilee District, Clalit Health Services

11.30 – 11.50
Epidemiology of hepatitis E. 1.5Mb (.pdf)
Eli Schwartz,  The Center for Travel Medicine and Tropical Diseases, Sheba Medical Center, Tel hashomer & Sackler School of Medicine Tel-Aviv Univ

11.50 – 12.00
Molecular epidemiology of hepatitis E.  230Kb (.pdf)
Nili Daudi,  The Liver Unit, Hadassah-Hebrew University Hospital, Jerusalem

Session 4 Epidemiology of hepatitis virus in special risk groups
Chair: Paolo Bonanni, Oren Shibolet

12.00 – 12.20
Hepatitis B and C in pregnancy in the Jewish and Arab populations.  2.4 Mb (.pdf)
Rifaat Safadi, Director, Liver Unit, Hadassah Hebrew University Hospital, Jerusalem

12.20   – 12.40
HIV and HCV Co-infection.  1Mb (.pdf)
Margalit Lorber,  Head, Autoimmune Disease Unit, Rambam Medical Center, Rappaport Faculty of Medicine, Technion, Haifa

12.40 – 13.00
Epidemiology of HCV and HIV infection in patients with coagulation disorders.  254Kb (.pdf)
Yaacov Maor,  Dept. of Gastroenterology and Hepatology, Kaplan Medical Center, Rehovot

13.00 – 13.20
Hepatitis viruses and HIV in intra-venous drug abusers.  584Kb (.pdf)
Paula Roska,  Head, Department for the Treatment Of Substance Abuse, MOH

13.20 – 13.30 Discussion

13.30 – 14.30  Lunch

Session 5 Prevention and Control of viral hepatitis in the country level
Chair: Mark Kane, Shmuel Rishpon

14.30 – 14.50
Prevention and control of HBV and HCV in healthcare workers.   785Kb (.pdf)
Bina Rubinowitch,  Head, Unit of Infection Prevention and Control, Rabin Medical Center, Petah-Tikva

14.50 – 15.10
Sero-prevalence of HBs antibodies 19 years after introduction of universal vaccination against HBV.  591Kb (.pdf)
Tamar Shohat,  Director, Israeli Center for Disease Control (ICDC), Ministry of Health

15.10 – 15.30
Prevention and control of hepatitis A and B in the Military
Michael Hartal, Head, Academy and Research Branch, Medical Corps, IDF

15.30 – 15.50
Screening for hepatitis B and C in Magen David Adom (MDA) - National Blood Services.   
Vered Yahalom,  Magen David Adom (MDA) - National Blood Services, Tel Hashomer

15.50 – 16.10 Discussion

16.10 – 16.30 Coffee Break

Session 6 Miscellaneous
Chair: Angela Dominguez,  Rifaat Safadi

16.30 – 16.50
Evidence for a rising burden of hepatocellular carcinoma.  2Mb (.pdf)
Oren Shibolet,  Director, Liver Unit, Tel-Aviv Medical Center

16.50– 17.10
Liver Transplantation for viral liver diseases in Israel.  270Kb (.pdf)
Michal Carmiel, Director, Liver Unit, Nahariya Medical Center

17.10 – 17.30
Patients Association: HETZ-The Israeli Association for the Health of the Liver.  1.9Mb (.pdf)
Julio Burman, The Israeli Association for the Health of the Liver, Kibbutz Tzora

17.30– 17.50 Discussion

Friday, March 15, 2013

Session 7   Vaccination programmes
Chair: John Ward, Daniel Shouval

09.00 – 09.20
The National Advisory Committee on Immunization and Infectious Diseases ( NACIID). 191Kb (.pdf)
Shmuel Rishpon, Head of the Advisory Committee on Infectious Diseases and Immunizations. Ministry of Health.

09.20 – 09.40
The national hepatitis A vaccination programme and the impact of universal immunization on the molecular epidemiology of HAV infection. 763Kb (.pdf)
Daniel Shouval,  Liver Unit, Hadassah-Hebrew University'. Ron Dagan, BenGurion University, Beer Sheba

09.40 – 10.00
Hepatitis A in Jerusalem : An exception which proves the rule?  1.7Mb (.pdf)
Chen Stein-Zamir, MOH District Officer, Jerusalem

10.00 – 10.20
An outbreak of hepatitis A in adults in Tel-Aviv district. 1.6 Mb (.pdf)
Matthew Lewis, Tel-Aviv Health District

10.20– 10.40 Discussion

10.40 – 11.00 Coffee break

11.00– 11.40
Development and utilization of the PreS/S hepatitis B vaccine in Israel. Bypass of non-response to conventional immunization against HBV using a Pre-S/S vaccine.  4.8Mb (.pdf)
Daniel Shouval, Liver Unit, Hadassah-Hebrew University hospital, Jerusalem, Israel

11.40– 12.00
Hepatitis B vaccines in patients on hemodialysis..   256Kb (.pdf)
Talia Weinstein, Head, Hemodialysis Unit, Tel Aviv Medical Center

12.00– 12.20
Concluding remarks on the prevention and control of viral hepatitis A, B and C in Israel 1972-2012.  190Kb (.pdf)
Daniel Shouval, Liver Unit, Hadassah-Hebrew University hospital, Jerusalem, Israel

12.20 – 12.40 Discussion

Session 8   Conclusions
Chair: Johannes Hallauer, Stefan Wiktor 

13.00 – 13.45
Presentation of the VHPB meeting conclusions   67Kb(.pdf)
David FitzSimons

14.00 Close of the meeting